Compare AstraZeneca plc (AZN) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs KB Financial Group, Inc. — how do they compare? AstraZeneca plc trades at $158.28 (market cap $248.14B), while KB Financial Group, Inc. trades at $117.63 (market cap $41.21B). The key difference: AstraZeneca plc is far larger — about 6× KB Financial Group, Inc.'s market cap, and KB Financial Group, Inc. pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| AZN | KB | |
|---|---|---|
Market Cap | $248.14B | $41.21B |
Sector | Health | Financials |
52-Week High | $209.48 | $124.01 |
52-Week Low | $147.06 | $77.50 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
KB Financial trades at $117.63, down 2.57% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and rising revenue ($21.23T in 2025). Valuation metrics appear attractive with a P/E of 10.36 and P/B below 1. Recent news highlights momentum and dividend potential, while cash flow trends show volatility with a net inflow of $4.41T in 2025.
The outlook remains positive given earnings momentum and diversification into non-banking segments (43% of earnings). Risks include volatile cash flows and macroeconomic sensitivity. Analysts are mixed (33% Buy, 67% Hold), suggesting cautious optimism. The stock's current price near support at $117 offers a potential entry, but investors should monitor execution on non-banking targets and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
